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Prevalence and load of airway bacteria in stable and exacerbated COPD has been previously 
studied using microbiological culture. Molecular techniques such as quantitative PCR (qPCR) 
may be more sensitive and informative.   
 
Methods: 
In this study, 373 sputum samples from 134 COPD outpatients were assessed for prevalence 
and load of typical airway bacteria (Haemophilus influenzae, Streptococcus pneumoniae, 
Moraxella catarrhalis) by multiplex qPCR, with 176 of these samples analysed for atypical 
bacteria (Chlamydophila pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae).  
Paired stable and exacerbation typical bacteria data were compared in 52 patients. We 
compared routine culture with qPCR in 177/373 samples.   
 
Results: 
Typical bacteria were more prevalent in exacerbation than stable state paired samples: 
30/52 (57.7%) vs. 14/52 (26.9%);p=0.001.  In patients who were bacteria-positive at both 
time points, mean (±1SEM) load was significantly higher at exacerbation than stable state 
(108.5(±0.3) vs. 107.2(±0.5) cfu/ml), constituting a 20-fold increase (p=0.011).  Quantitative PCR 
was more discriminatory at detecting typical bacteria than microbiological culture 
(prevalence 59.3% vs. 24.3%;p<0.001). In the stable state, higher airway bacterial load 
correlated with more severe airflow limitation (FEV1%predicted) (r=-0.299;p=0.033) and 
with higher inhaled corticosteroid dosage (r=0.382;p=0.008).  Mean CRP was higher in those 
exacerbations which were associated with bacteria (35.0 Vs 25.1 mg/L;p=0.032). Atypical 
bacteria prevalence was low at 1% at exacerbation. 
  
Conclusions:  
Airway bacterial prevalence and load increase at COPD exacerbations and are an aetiological 
factor.  Quantitative PCR is more discriminatory than culture, identifying higher airway 
bacterial prevalence. Exacerbations associated with bacterial detection showed a higher 
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mean CRP level. In the stable state, airway bacterial load is related to more severe airflow 




Chronic obstructive pulmonary disease (COPD) is an inflammatory condition caused by an 
abnormal response to noxious gases and particles [1]. COPD is associated with considerable 
global morbidity and mortality and it has been projected to be the fourth highest cause of 
death by 2030 [2].  Acute exacerbations of COPD are episodes which are characterised by a 
worsening of respiratory symptoms associated with variable degrees of physiological 
deterioration [3].   These events are a major cause of morbidity and mortality globally, and 
COPD exacerbations are a leading cause of hospital admissions [3].  
 
Lower airway bacterial colonisation (LABC) is a common and important feature of COPD and 
the commonly isolated organisms are Streptococcus pneumoniae, Haemophilus influenzae 
and Moraxella catarrhalis [4,5], although most studies investigating LABC have used culture 
techniques.  LABC has been shown to be related to an increase in airway inflammation, 
exacerbation frequency and lung function decline [5–8]. 
 
Previous studies suggest that the majority of exacerbations have an infectious aetiology – 
with approximately half of these events associated with culture of potentially pathogenic 
airway bacteria, similar to those found in the stable state [9].  Positive cultures of 
Pseudomonas aeruginosa have also been shown to be associated with COPD but more 
commonly in advanced disease [10].  
 
To date, the vast majority of analysis of bacterial prevalence and load has been based on 
culture but there is little on PCR comparison with culture.  The use of culture-independent 
techniques such as quantitative PCR (qPCR) has not been extensively studied in the context 
of atypical airway bacteria, which are characteristically difficult to culture (Chlamydophila 
pneumoniae, Legionella pneumophila and Mycoplasma pneumoniae) with one previous 
study showing no association with COPD exacerbations [11].  Conversely, serological 




The objective of this study was to investigate the prevalence and load of typical and atypical 
airway bacteria in COPD using modern molecular techniques.  We also analysed prevalence 
and load at the stable and exacerbation states, and compared qPCR with routine 






This study involved 134 subjects enrolled in the London COPD cohort between January 2007 
and March 2011.  The patients form part of a rolling cohort used to prospectively investigate 
the mechanisms and aetiology of COPD exacerbations, as previously described by our group 
[14].  Patients were included if the forced expiratory volume in one second (FEV1) was ≤80% 
predicted and FEV1/forced vital capacity (FVC) ratio was <0.7, in keeping with GOLD stages 
II-IV [1].  A history of chronic symptoms (dyspnoea, sputum production, wheeze and cough) 
was taken, as well as smoking history (number of pack-years smoked, current smoking 
status).  Patients with a history of any other significant respiratory diseases were excluded, 
as were those unable to complete daily diary cards.  
 
Definitions of Clinical States 
An exacerbation was defined as new or increased respiratory symptoms for two or more 
consecutive days, with at least one major symptom (dyspnoea, sputum purulence and 
sputum volume) and another major or a minor symptom (wheeze, cold, sore throat and 
cough), the first day of which was defined as the day of onset of the exacerbation.  Stable 
state was defined as no symptom-defined exacerbations for the preceding four weeks and 
the subsequent two weeks post-clinic visit. 
 
Clinical assessment 
Spirometry was performed in accordance with ATS/ERS guidelines, using a volumetric 
storage spirometer (Vitalograph 2160, Maids. Moreton, Buckingham, UK).  FEV1 was 
expressed as a percentage of that predicted from age, height and sex.  Serum C-reactive 
protein (CRP) quantification was performed to assess systemic inflammation, using Modular 
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Analytics E 170 Module (Roche, burgess Hill, UK).  Patients recorded inhaled corticosteroid 
dosage and usage daily on diary cards.  Due to variations in dosage by different medications, 





Sputum collection and processing 
 
Sputum was spontaneously expectorated into a sterile pot in the stable state and/or at 
exacerbation.  All exacerbation visits occurred within 7 days of exacerbation symptom 
onset.  Patient samples were used in a number of different analyses (Figure 1). 
 
Following expectoration, sputum plugs were separated from saliva using sterile forceps, 
with one-third being taken for culture analysis where there was sufficient quantity. The 
remaining sputum was weighed and suspended in nine times volume of standard isotonic 
phosphate-buffered saline (PBS).  Glass beads were added to this suspension and it 
underwent homogenisation by vortexing for 15 seconds, rocking for 15 minutes (IKA Vibrax 
VXR, Staufen, Germany) and additional vortexing for 15 seconds.  Aliquots of 500µl were 
taken for storage at -80oC for subsequent batch processing.   
 
Routine microbiological culture 
Qualitative bacterial culture was carried out by the Department of Medical Microbiology, 
Royal Free Hampstead NHS Trust, London.  Briefly, sputum was cultured onto suitable agar 
for 24 hours at 37oC and 5% CO2.  Agar types used were Columbia blood agar (general 
growth media), Chocolate agar (growth of fastidious bacteria), MacConkey agar (growth of 
gram-negative bacteria) and COBA agar (growth of Streptococcus spp.).  S. pneumoniae was 
identified through optochin sensitivity testing.  
 
DNA extraction 
Homogenised sputum samples underwent heat-kill treatment at 90oC for 30 minutes, 
before being microfuged at 13000g for 10 minutes.  The pellet was washed in 1ml PBS and 
spun at 13000g for 10 minutes, before removal of supernatant and re-suspension of the 
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pellet in 200μl of PCR-grade UV-sterilised water (Sigma-W4502).  To each sample, 200μl of 
10% Chelex 100 (Sigma C-7901) was added.  Samples were incubated for 20 minutes in a 
heat block at 56oC.  Samples were heated at 95oC for five minutes prior to cooling on ice.  
Samples were then spun in a microfuge at 16000g for 10 minutes.  Supernatant, containing 
extracted DNA, was transferred to a fresh UV-sterilised 1.5ml tube and stored at 4oC. 
 
Multiplex quantitative PCR detection of bacteria 
 
Real-time multiplex qPCR was performed on S. pneumoniae, H. influenzae and M. 
catarrhalis, targeting Spn9802 (gene fragment); Haemophilus influenzae P4 lipoprotein 
gene; and copB outer-membrane-protein gene, respectively.  Both Spn9802 [16] and copB 
[17] profiles used previously validated qPCR primers and probes, ensuring no cross-
reactivity with related oral species.  The H. influenzae P4 lipoprotein gene target was 
established in-house. This was confirmed to have no cross-reactivity with other 
Haemophilus species as well as a number of Streptococcus spp, Moraxella catarrhalis, 
Bordatella pertussis, Candida spp., Pseudomonas aeruginosa, Escherichia coli, Neisseria 
meningitidis, Acinetobacter spp, Legionella pneumoniae, Klebsiella pneumoniae, methicillin-
resistant Staphylococcus aureus  and Corynebacterium diphtheriae.  An internal 
amplification control (IAC), targeting the PhyB gene of Solanum tuberosum, was utilised in 
order to detect any PCR inhibition, incorporated in the PCR mastermix [18].  The following 
positive control strains were used: S. pneumoniae ATCC strain 49619; H. influenzae ATCC 
strain 10211; M. catarrhalis ATCC strain 25238. The minimum limit of detection used in this 
study was 104 colony forming units (cfu)/ml. 
 
A separate multiplex qPCR was performed to detect C. pneumoniae, L, pneumophila and M. 
pneumoniae, targeting RNA-polymerase β-chain gene; MIP gene; and P1 adhesin protein 
gene, respectively.  C. pneumoniae primer/probe set was a previously validated set  [19].  M. 
pneumoniae and L. pneumophila were developed in-house and shown to have no cross-
reactivity with related species and other oral flora. The PCR was performed with two types 
of mastermix, one of which was spiked with an IAC (L. pneumophila DNA). Primer and probe 
details are listed in Web only files in the appendix.  Normalisation of qPCR results was 
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performed by correcting Ct values of the IAC in positive samples according to its 





Data were analysed using PASW Statistics v.18 (SPSS Inc., Chicago, USA).  The Kolmogorov-
Smirnov test for normality was applied. Clinical data with normal distribution are described 
in mean (±SD).  Differences between groups were analysed by independent-samples t-test, 
paired-samples t-test, Mann-Whitney U test or one-way ANOVA, dependent upon the 
sample population being investigated. Relationships between continuous variables were 
analysed using Pearson’s or Spearman’s correlation in a univariate analysis, or by linear 
regression in a multivariate analysis.  Frequency distribution was explored by χ2-analysis.  A 




The study was approved by the Royal Free Research Ethics Committee and all patients gave 







Sputum samples from 134 COPD patients were examined.  There were no clinically or 
statistically important differences in stable state clinical characteristics between the sub-







    COPD Patient Sub-groups     
                      
    Typical bacteria 
analysis (n=134) 
  Culture 
analysis (n=74) 
  Atypical bacteria 
analysis (n=80) 
  Paired analysis 
(n=52) 
    
            p-value 
                      
                      
FEV1 (l)   1.22 (±0.52)   1.20 (±0.5)   1.11 (±0.50)   1.15 (±0.50)   p=0.407 
                      
FEV1/FVC (%)   45.8 (±12.9)   45.2 (±12.6)   43.8 (±13.4)   43.4 (±13.4)   p=0.596 
                      
Predicted FEV1 (%)   48.5 (±18.1)   48.5 (18.3)   45.4 (±17.8)   46.4 (±17.5)   p=0.582 
                      
Current smoker 
(%) 









        
       
Age (years)   69.8 (±8.7)   69.8 (±8.3)   70.1 (±8.9)   68.7 (±8.5)   p=0.840 
                      
Male gender (%)   64   69   68   61   p=0.773 
                      
Pack years 
smoking 










Table 1.  Stable-state clinical characteristics of COPD patient sub-groups.  No significant differences were seen between 
the groups.  Paired analysis refers to patients with paired stable and exacerbation state samples (the nearest stable state 
sample prior to exacerbation was used in this analysis). Data is presented as percentage value or mean±SD as appropriate. 
 
 
Typical bacteria prevalence and load determined by quantitative PCR 
 
Typical bacterial prevalence by qPCR was higher in exacerbation sputum samples compared 
to stable samples (74/131 bacterial isolates (56.5%) vs. 107/242 (44.2%) respectively, 
p=0.024). 
 
In samples positive for bacteria, mean (±1SEM) typical bacteria count was significantly 
higher during exacerbation, at 108.3(±0.2) cfu/ml (in absolute numbers 2x108 cfu/ml), 
compared to the stable state, with 107.3(±0.2) cfu/ml (in absolute numbers 2x107 cfu/ml), a 
10-fold increase, and significantly different (p<0.001) in an unpaired analysis (Figure 2).  H. 
influenzae was the most prevalent species, both in the stable state (21.9%) and at 
exacerbation (26.0%).  M. catarrhalis was significantly more prevalent at exacerbation 
(16.8%) compared with the stable state (7.4%) (p=0.005). Mean (±1SEM) bacterial load of 
both S. pneumoniae and H. influenzae was significantly higher at exacerbation than at stable 
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state: 108.1(±0.3) vs. 107.2(±0.3) cfu/ml, p=0.043 and 108.2(±0.2) vs. 107.0(±0.2) cfu/ml, p<0.001, 
respectively. 
  
Typical bacteria prevalence and load in paired stable and exacerbation samples 
 
Fifty-two pairs of stable and exacerbation samples from 52 patients showed significantly 
higher cumulative prevalence of typical bacteria at exacerbation compared with the stable 
state (67.3% vs. 30.8%; p<0.001).  Fourteen stable state samples (26.9%) were positive for at 
least one bacterium compared with 30 exacerbation state samples (57.7%) (p=0.001).  In 
paired samples which were bacteria-positive at both stable and exacerbation state (n=12), 
the mean load was approximately 20-fold higher at exacerbation than in the stable sample 
(108.5(±0.3) vs. 107.2(±0.5) cfu/ml) (p=0.011) (Figure 3B).   
 
The species detected with highest prevalence was H. influenzae at stable state (11/52, 
21.2%), with S. pneumoniae most frequently seen at exacerbation (13/52, 25%) (Figure 3A). 
M. catarrhalis showed a significant increase in prevalence at exacerbation (10/52, 19.2%), 
increasing from 2/52 (3.8%) at the stable state (p=0.014).  S. pneumoniae prevalence was 
significantly higher at exacerbation (13/52, 25.0%) than during stable state (3/52, 5.8%) 
(p=0.002). 
 
Comparison of Quantitative PCR with culture for the detection of typical bacteria 
 
Culture and qPCR for typical bacteria were compared in 177 samples (105 stable and 72 
exacerbation samples) from 74 patients. 
 
Quantitative PCR was far more discriminatory at detecting typical bacteria than culture 
(105/177 positive samples (59.3%), vs. 43/177 (24.3%), p<0.001). This finding was replicated 
in terms of individual bacterial species: H. influenzae 30.5% PCR-positive vs. 15.8% culture-
positive, (p=0.001); S. pneumoniae 14.1% vs. 5.1%, (p=0.004); M. catarrhalis 14.7% vs. 3.4%, 




Positive culture identification and negative qPCR identification was seen for H. influenzae in 
4/177 samples (2.3%); for S. pneumoniae in 4/177 samples (2.3%); for M. catarrhalis in 
1/177 samples (0.6%). 
 
Effect of typical bacteria on lung function in stable state and at exacerbation 
 
Higher bacterial load was significantly correlated to disease severity in the stable state (FEV1 
%predicted); r=-0.299; p=0.033 (Figure 5).  In a multivariate analysis, the relationship 
between FEV1 and airway bacterial load remains significant after allowance of either age 
(p=0.036) or smoking status (p=0.046), although it just misses statistical significance when 
both age and smoking status are included in the model (p=0.057). 
 
Percentage (±SD) change in FEV1 (from stable state) with H. influenzae-associated 
exacerbations (n=10) was -17.4% (±15.8%), and in exacerbations which had no H. influenzae 
presence (n=47), the change was -5.9% (±20.0%).  This difference was not statistically 
significant (p=0.09).  
 
Airway bacterial load association with inhaled corticosteroid usage   
 
Forty-seven (92.2%) patients who had bacteria detected in the stable state had inhaled 
corticosteroid usage recorded:  Median (IQR) beclomethasone-equivalent dosage was 2000 
(640-2000) µg daily.  In a univariate analysis, higher airway bacterial load was also 
significantly correlated to higher inhaled corticosteroid dosage (corrected for 
beclomethasone equivalence); r=0.382; p=0.008.  This relationship remains significant in a 
multivariate analysis including age, smoking status and FEV1 % predicted (p=0.022). 
 
Systemic inflammation is related to airway bacterial presence during exacerbations 
 
Levels of C-reactive protein (CRP), a marker of systemic inflammation, are significantly 
related to presence of typical airway bacteria at exacerbation.  CRP was measured in 119 
exacerbation samples.  Exacerbations with bacterial detection (n=58) showed significantly 
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higher mean CRP compared to exacerbations with no bacterial detection (n=61); 35.0 vs. 
25.1 mg/L, p=0.032.  
 
Analysis of COPD patient samples for atypical bacteria 
 
A total of 176 samples, from 80 patients, were investigated for presence of the atypical 
bacteria (Chlamydophila pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae).  
Of these, 97 were stable samples and 79 were exacerbation samples.  Five samples were 
positive for Legionella pneumophila (4 stable, 1 exacerbation) and one stable sample was 
positive for Mycoplasma pneumoniae.  No relationship was observed between atypical 
bacterial load and clinical outcome: Mean bacterial load for L. pneumophila was 104.37(±0.4) 




This is the largest study to date to use molecular techniques for detection of airway bacteria 
and also the first to complimentarily evaluate typical and atypical bacteria in a well-
characterised cohort of COPD patients. We have explored the relationship between airway 
bacterial prevalence and load in stable COPD patients and at exacerbations.  At 
exacerbation there is a marked increase in bacterial load in colonised patients, with an 
absolute increase in the region of 20-fold being identified in positive samples.  We have 
conclusively demonstrated that qPCR is more discriminatory than culture at detecting 
typical airway bacteria.  The role of atypical pathogens in COPD is minor, having been 
detected at low prevalence and load in very few samples.  
 
We have found that in the stable state, there is a total prevalence rate for the three typical 
bacteria analysed together of 44.2%.  H. influenzae was the most prevalent species 
identified.  H. influenzae is also the most prevalent species in culture based studies [4,20].  
The prevalence rate using qPCR in this study is higher than prevalence in such culture 
studies.  This work also highlights the association of airway bacteria with a poorer disease 
outcome in COPD and our previous findings that increased airways inflammation may relate 
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to airway bacterial colonisation [5] and is associated with faster FEV1 decline [8].  In the 
stable state, we found significant correlation between higher bacterial load and more severe 
airflow limitation, independent of age or smoking status.   
 
One previous study compared detection frequency of typical airway bacteria by qPCR and 
routine microbiological culture in COPD patients, evaluating 30 samples [21].  In a larger 
dataset, we have now confirmed that qPCR is significantly more discriminatory than culture 
at detecting each of these three main airway bacteria.  It is known that H. influenzae is able 
to persist intracellularly in the respiratory tract, with possible resultant culture-negative 
sputum [22,23].  There were some instances in this study where a sample was culture-
positive and PCR-negative and there are a number of potential explanations for this, 
including technical issues with the primer targets, operator error, or sampling, although the 
rates of such culture-positive PCR-negative samples were actually very low in our study. 
Quantitative PCR is therefore the most appropriate method to determine bacterial 
prevalence and load, with little additional sensitivity to be gained from running both 
methods in tandem. 
 
The advantage of qPCR is that it gives a higher rate of detection than culture.  Using this 
technique, this study demonstrates that exacerbations in COPD are characteristically 
associated with both increased prevalence and load of typical bacteria.  This confirms 
previous data suggesting that the increase in load and acquisition of bacteria seen at 
exacerbation is driving such exacerbations [24].  Microbiological culture is however useful in 
other aspects of bacteriology, such as in the identification of antibiotic resistance and so 
should not be wholly discounted. One limitation of PCR microbiological technique is that 
they can detect both viable and non-viable bacteria, while culture detects viable bacteria 
alone.  However, to our knowledge, no studies have shown non-viable bacteria to be 
present at levels of 104 cfu/ml (the lower limit of detection for our PCR assays).  Alveolar 
macrophages are responsible for clearance of DNA from the lungs, and so it is unlikely that 
DNA from lysed cells would persist for long periods. 
 
It has also been previously demonstrated that airway bacterial presence is associated with 
increases in inflammatory cytokines [7,25,26].  We have found that bacterial presence at 
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exacerbation detected by PCR is significantly associated with higher systemic inflammation 
using serum CRP.  We also found a trend to increased fall in FEV1 with HI-associated 
exacerbations, probably due to increased airway inflammation, and this is consistent with 
our previous data [24].    Many exacerbations of COPD also have a viral aetiology and prior 
studies have demonstrated that exacerbations involving co-infection with bacteria and 
viruses are associated with a more impaired lung function [24,27].   
 
We also conclusively quantified typical airway bacteria in a cohort of COPD patients, with a 
concomitant illustration of significant increases in prevalence and load of three of the most 
commonly isolated bacteria seen in such subjects.  This provides further support to previous 
studies which hypothesise that alterations in ‘normal’ bacterial colonisation may trigger 
acute exacerbations of COPD [28].  This study has not examined the strain-switching 
hypothesis previously put forward [29].  However, strain-acquisition is associated with an 
increase in bacterial load.  Further work is needed to explore whether differences in stable 
and exacerbation loads are related to the same strain or different strains of specific 
bacterial species.    
 
For the first time, we have also shown a significant relationship between airway bacterial 
load and inhaled corticosteroid dosage at the time of sampling in stable patients; this effect 
was independent of age, smoking status and disease severity.  Findings from the TORCH and 
INSPIRE randomised controlled trials have indicated that inhaled corticosteroid use is 
related to increased frequency of developing pneumonia in COPD patients [30–32].  Our 
data suggests that the increase in airway bacterial colonisation may play a part in increasing 
susceptibility to pneumonia in COPD.  
 
This study was limited to the three most commonly detected organisms and it is probable 
that other organisms also contribute to the microbiome.  However, recent detailed studies 
in small numbers of subjects have identified only the presence of commensals in addition to 
the common bacteria we studied and it is unlikely that other bacteria are playing a 
significant role [28,33,34].  Pseudomonas aeruginosa was not studied in this analysis as its 
culture detection rate is very low in the London COPD cohort (<1%).  Further work is needed 
to explore whether differences in stable and exacerbation loads are related to the same 
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strain or different strains of specific bacterial species.  It is also difficult to differentiate 
between those strains that were infective and those which were colonising, due to the fact 
that colonising strains are very likely to also appear at exacerbation.  The different 
methodological approaches required are beyond the scope of this study.  
 
The potential role of atypical bacteria in COPD was important to investigate with qPCR as 
they are characteristically difficult to culture, and if found at high prevalence or load, could 
have major implications for therapy.  A previous study found little evidence of atypical 
bacteria colonisation in a qPCR analysis of 248 sputum samples from COPD patients, with 
just one sample positive for Legionella spp. [11].  The current study investigated the rate of 
these bacteria in COPD patients and found low prevalence, with one exacerbation sample 
(1.3%) identified with presence of L. pneumophila.  Atypical bacteria are therefore not major 
pathogens in COPD either in the stable state or at exacerbation, and do not need specific 
therapy. 
 
This study shows that at COPD exacerbations, airway bacterial prevalence and load increase 
significantly and are an important aetiological factor driving the event.  The presence of 
increased total bacterial load in the stable state and relationship to disease progression 
suggests that targeted antibiotic therapy for colonised patients may be beneficial.  
Quantitative PCR is more discriminatory than culture, identifying higher airway bacterial 
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Figure 1  
COPD patient groups analysed. Patients may have been in more than one subanalysis. For 
paired analysis, stable samples were obtained <365 days prior to exacerbation (the nearest 




Quantitative PCR comparison of load of typical airway bacteria in stable COPD (n=242) and 
exacerbation (n=131) in unpaired samples. Species: SP = Streptococcus pneumoniae; MC = 






Figure 3  
(A) Prevalence of typical airway bacteria in paired samples from COPD patients at both 
stable and exacerbation (n=65). (B) Overall bacterial load at stable state and exacerbation, 
in patients positive for typical airway bacteria at both states (n=12). Species: SP = 







Figure 4  
Comparison of culture and qPCR detection of three typical airway bacteria in sputa from 177 
COPD patients (105 stable, 72 exacerbation). Species: HI = Haemophilus influenzae, SP = 
Streptococcus pneumoniae; MC = Moraxella catarrhalis.  
 
 
Figure 5  
Association of bacterial load with FEV1 in stable colonised patients (n=51). This illustrates 
the association of lower FEV1 status in patients with higher bacterial loads. Data with FEV1% 
predicted >80% were from patients who had FEV1% predicted <80% at recruitment. 
